FDA Clears Zohydro Single-Entity Hydrocodone Without Abuse Deterrence Properties
This article was originally published in The Pink Sheet Daily
Advisory committee had recommended against approval before the agency imposed additional post-marketing study requirements on the extended-release/long-acting opioid class.
You may also be interested in...
Opioid issues delayed Robert Califf’s confirmation as FDA commissioner. Could they prevent the nomination of Janet Woodcock?
A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.